EP3291798A4 - LYOPHILIZED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND PREPARATION METHOD THEREOF - Google Patents

LYOPHILIZED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND PREPARATION METHOD THEREOF Download PDF

Info

Publication number
EP3291798A4
EP3291798A4 EP15891266.7A EP15891266A EP3291798A4 EP 3291798 A4 EP3291798 A4 EP 3291798A4 EP 15891266 A EP15891266 A EP 15891266A EP 3291798 A4 EP3291798 A4 EP 3291798A4
Authority
EP
European Patent Office
Prior art keywords
rifabutin
preparation
pharmaceutical formulation
lyophilized pharmaceutical
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15891266.7A
Other languages
German (de)
French (fr)
Other versions
EP3291798A1 (en
Inventor
Mitesh Natavarlal Patel
Mafatlal Tribhovandas DAVE
Pranavkumar Jayesh Choksi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gufic Biosciences Ltd
Original Assignee
Gufic Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gufic Biosciences Ltd filed Critical Gufic Biosciences Ltd
Publication of EP3291798A1 publication Critical patent/EP3291798A1/en
Publication of EP3291798A4 publication Critical patent/EP3291798A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP15891266.7A 2015-05-04 2015-09-07 LYOPHILIZED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND PREPARATION METHOD THEREOF Withdrawn EP3291798A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1770MU2015 2015-05-04
PCT/IN2015/000348 WO2016178240A1 (en) 2015-05-04 2015-09-07 A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof

Publications (2)

Publication Number Publication Date
EP3291798A1 EP3291798A1 (en) 2018-03-14
EP3291798A4 true EP3291798A4 (en) 2019-01-16

Family

ID=57218191

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15891266.7A Withdrawn EP3291798A4 (en) 2015-05-04 2015-09-07 LYOPHILIZED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND PREPARATION METHOD THEREOF

Country Status (3)

Country Link
EP (1) EP3291798A4 (en)
EA (1) EA201792417A1 (en)
WO (1) WO2016178240A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4027976T (en) 2019-09-12 2026-01-12 BioVersys AG Rifabutin compositions and method of making
US11351158B2 (en) 2019-09-12 2022-06-07 BioVersys AG Rifabutin treatment methods, uses, and compositions
US11344537B2 (en) 2019-09-18 2022-05-31 BioVersys AG Rifabutin treatment methods, uses, and compositions
WO2026022215A1 (en) 2024-07-23 2026-01-29 BioVersys AG Lyophilized formulations of rifabutin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013569B1 (en) * 2009-02-24 2010-06-30 Ооо "Научно-Производственный Комплекс "Наносистема"" Pharmaceutical composition of rifabutin for treating tuberculosis and other diseases mediated by helicobacter pylori, method of production thereof and method for treatment thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
RU2327457C1 (en) * 2007-06-26 2008-06-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Medicinal agent based on rybafutin, agent of antimicrobic action containing nanoparticles, and related method of production
PT2247291T (en) * 2008-02-08 2019-02-01 Red Hill Biopharma Ltd Methods and compositions for treating inflammatory bowel disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013569B1 (en) * 2009-02-24 2010-06-30 Ооо "Научно-Производственный Комплекс "Наносистема"" Pharmaceutical composition of rifabutin for treating tuberculosis and other diseases mediated by helicobacter pylori, method of production thereof and method for treatment thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016178240A1 *

Also Published As

Publication number Publication date
EA201792417A1 (en) 2018-04-30
EP3291798A1 (en) 2018-03-14
WO2016178240A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
EP3437637A4 (en) PHARMACEUTICAL PREPARATION OF PALBOCICLIB AND PREPARATION METHOD THEREOF
EP3524603A4 (en) INHIBITOR OF FGFR4, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
IL264439A (en) Nucleic acid products and methods of administering them
EP3643491A4 (en) COMPOSITE FLOOR AND PREPARATION METHOD THEREOF
EP3305292A4 (en) MEK INHIBITOR PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF
MA43835A (en) PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINAL PRODUCTS AND THEIR INTERMEDIARIES
EP3353841A4 (en) PROCESS FOR THE PREPARATION AND APPLICATION OF CARBON-SELENIUM COMPOSITES
EP3653202A4 (en) PHARMACEUTICAL PREPARATION AND ITS PREPARATION PROCESS
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
EP3556371A4 (en) PHARMACEUTICAL COMPOSITION OF SULFONYL URINE MEDICINAL PRODUCTS AND METHOD OF MANUFACTURING THEREFORE
EP3395329A4 (en) PROCESS FOR THE PREPARATION OF LIPID BODIES AND THEIR USE
EP3560518A4 (en) COMPLEX FOR ADMINISTRATION AND STABILIZATION OF MEDICINAL PRODUCTS AND METHOD FOR MANUFACTURING THEREOF
EP3398615A4 (en) MUCOADHETIC PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING THE SAME
EP3498716A4 (en) THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF
EP3485886A4 (en) PHARMACEUTICAL COMPOSITION OF TECOVIRIMAT FOR ORAL ADMINISTRATION AND ITS PREPARATION METHOD
EP3527195A4 (en) PHARMACEUTICAL PREPARATION CONTAINING POLYETHYLENE GYLCOL LOXENATIDE AND PREPARATION METHOD THEREOF
MX385925B (en) HIGH PURITY ORITAVANCIN AND METHOD FOR PRODUCING SAME.
EP3485887A4 (en) PHARMACEUTICAL COMPOSITION OF TECOVIRIMAT FOR INTRAVENOUS DELIVERY AND METHOD OF PREPARATION
EP3388433A4 (en) PHTHALAZINE DERIVATIVE AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3459948A4 (en) FLUORINE-CONTAINING TRIAZOLOPYRIDINE AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
EP3291798A4 (en) LYOPHILIZED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND PREPARATION METHOD THEREOF
ZA201805080B (en) Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
EP3486338A4 (en) FLAKE MICROCAPSULE AND PREPARATION METHOD THEREOF
EP3378493A4 (en) NOVEL NANOPREPARATION OF ANTICANCER DRUG AND PREPARATION METHOD THEREOF
EP3329910A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ONYCHOMYCOSIS AND PREPARATION METHOD THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20171106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181217

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/435 20060101ALI20181207BHEP

Ipc: A61K 9/19 20060101AFI20181207BHEP

Ipc: A61K 47/26 20060101ALI20181207BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190719